RxDoctor Payments Data

Kyle Eskridge

Rheumatology · Wading River, NYNPI 1649740374

Payments from drug & device makers

$21,085in general payments, 2019–2025

Across 819 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Johnson & Johnson$4K
  • AbbVie$3K
  • Mallinckrodt Hospital Products Inc.$2K
  • Pfizer$1K
  • UCB, Inc.$875
  • plus $5K from 25 others

What the payments were for

  • Speaking & faculty fees$6333%
  • Food & beverage$19,97495%
  • Education$4782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,085 in reported general payments places this provider in the 75th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib54$452,022
Enbrel SureclickEtanercept31$299,018
TremfyaGuselkumab13$175,896
Xeljanz XrTofacitinib Citrate32$172,972
Diclofenac Sodium120$138,957
Humira(Cf) PenAdalimumab21$137,423
OtezlaApremilast27$119,537
Cosentyx Sensoready (2 Pens)Secukinumab13$98,040
Orencia ClickjectAbatacept16$89,021
BenlystaBelimumab14$66,046
ProliaDenosumab11$19,073
Leflunomide219$17,899
Hydroxychloroquine Sulfate310$17,448
MethotrexateMethotrexate Sodium203$6,735
Gabapentin376$5,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,890$452,02254 claims
Johnson & JohnsonTremfya$3,551$175,89613 claims
AmgenOtezla, Prolia$5,257$138,61038 claims
GSKBenlysta$476$66,04614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 541 rheumatology providers in New York.

Other rheumatology in Wading River

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →